Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, Palena C, Schlom J (2020) Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances. J Immunother Cancer 8:e000433. https://doi.org/10.1136/jitc-2019-000433

Article  PubMed  PubMed Central  Google Scholar 

Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13:5262–5270. https://doi.org/10.1158/1078-0432.CCR-07-1157

CAS  Article  PubMed  Google Scholar 

Tzavlaki K, Moustakas A (2020) TGF-beta signaling. Biomolecules 10:487. https://doi.org/10.3390/biom10030487

CAS  Article  PubMed Central  Google Scholar 

Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF (1995) The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem 270:2747–2754. https://doi.org/10.1074/jbc.270.6.2747

CAS  Article  PubMed  Google Scholar 

Vugmeyster Y, Wilkins J, Koenig A, El Bawab S, Dussault I, Ojalvo LS, De Banerjee S, Klopp-Schulze L, Khandelwal A (2020) Selection of the recommended phase 2 dose for bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. Clin Pharmacol Ther 108:566–574. https://doi.org/10.1002/cpt.1776

CAS  Article  PubMed  PubMed Central  Google Scholar 

Vugmeyster Y, Klopp-Schulze L, Rueckert P, Khandelwal A, Speit I, Osada M, Grenga I (2020) Safety and pharmacokinetics of bintrafusp alfa with Q3W dosing: confirmation of the model-informed dose selection. ACOP 2020 Virtual Conference; November 9–13, 2020

Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, Lin CC, Flor MJ, Di Nicola M, Alvarez RM, Dussault I, Helwig C, Ojalvo LS, Gulley JL, Cho BC (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J Thorac Oncol 15:1210–1222. https://doi.org/10.1016/j.jtho.2020.03.003

CAS  Article  PubMed  PubMed Central  Google Scholar 

Strauss J, Braiteh FS, Calvo E, Miguel MD, Cervantes A, Edenfield WJ, Li T, Rasschaert MA, Park-Simon T-W, Longo F, Paz-Ares LG, Spira AI, Jehl G, Dussault I, Ojalvo LS, Gulley JL, Allan SW (2021) Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies. J Clin Oncol 39 (15_suppl):5509. https://doi.org/10.1200/JCO.2021.39.15_suppl.5509

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res 24:1287–1295. https://doi.org/10.1158/1078-0432.CCR-17-2653

CAS  Article  PubMed  PubMed Central  Google Scholar 

Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M (2020) Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 8:e000564. https://doi.org/10.1136/jitc-2020-000564

Article  PubMed  PubMed Central  Google Scholar 

Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, Kudo M (2020) Phase I study of the bifunctional fusion protein bintrafusp alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort. Oncologist 25:e1292-e1302. https://doi.org/10.1634/theoncologist.2020-0249

Rolfo C, Greillier L, Veillon; R, Badin F, Ghiringhelli F, Isambert N, Paulus A, Lambrechts M, Chaudhary S, Xiaoli You X, Vugmeyster Y, Helwig C, Hiret S (2021) Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study, Poster 465. Paper presented at the Society for Immunotherapy fo Cancers 37th Annual Meeting, Washington, DC; November 10–14, 2021

Gulley JL, Lacouture ME, Spira A, Verdaguer Mata H, Yoo C, Cho BC, Helwig C, Halady T, Valencia C, Bajars M, Strauss J, Brownell I (2021) 1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: treatment guidelines based on experience in clinical trials. Ann Oncol 32:S1181. https://doi.org/10.1016/j.annonc.2021.08.1661

Article  Google Scholar 

Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9:e90353. https://doi.org/10.1371/journal.pone.0090353

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ (2021) Novel therapies emerging in oncology to target the TGF-beta pathway. J Hematol Oncol 14:55. https://doi.org/10.1186/s13045-021-01053-x

CAS  Article  PubMed  PubMed Central  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. https://doi.org/10.1038/s41571-019-0218-0

CAS  Article  PubMed  Google Scholar 

Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX (2017) Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8:730. https://doi.org/10.3389/fphar.2017.00730

CAS  Article  PubMed  PubMed Central  Google Scholar 

Mitra MS, Lancaster K, Adedeji AO, Palanisamy GS, Dave RA, Zhong F, Holdren MS, Turley SJ, Liang WC, Wu Y, Meng YG, Vernes JM, Schutten MM (2020) A potent pan-TGFβ neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys. Toxicol Sci 175:24–34. https://doi.org/10.1093/toxsci/kfaa024

CAS  Article  PubMed  Google Scholar 

Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9:4479–4499. https://doi.org/10.2147/DDDT.S86621

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kewan T, Covut F, Ahmed R, Haddad A, Daw H (2020) Clinically significant bleeding with immune checkpoint inhibitors: a retrospective cohort study. Eur J Cancer 137:285–287. https://doi.org/10.1016/j.ejca.2020.07.005

CAS  Article  PubMed  Google Scholar 

Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H (2011) Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 104:413–418. https://doi.org/10.1038/sj.bjc.6606074

CAS  Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I (2017) Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. Clin Pharmacol Ther 101:582–584. https://doi.org/10.1002/cpt.628

CAS  Article  PubMed  Google Scholar 

Dai HI, Vugmeyster Y, Mangal N (2020) Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther 108:1156–1170. https://doi.org/10.1002/cpt.1953

CAS  Article  PubMed  PubMed Central  Google Scholar 

ICH (2020) Introductory Guide for Standardised MedDRA Queries (SMQs) Version 23.0. https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_23_0_English.pdf. Accessed November 2021

Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8:659–671. https://doi.org/10.1080/19420862.2016.1156829

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, Speer CP, Poelmann RE, Gittenberger-de Groot AC (2001) Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103:2745–2752. https://doi.org/10.1161/01.cir.103.22.2745

CAS  Article  PubMed  Google Scholar 

Langer JC, Henckaerts E, Orenstein J, Snoeck HW (2004) Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function. J Exp Med 199:5–14. https://doi.org/10.1084/jem.20030980

CAS  Article  PubMed  PubMed Central  Google Scholar 

Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, Clementelli C, Denis JF, Rahman AH, Tremblay G, Mascarenhas J, Mesa RA, O’Connor-McCourt M, Migliaccio AR, Hoffman R (2021) TGF-beta1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight 6:e145651. https://doi.org/10.1172/jci.insight.145651

Article  PubMed  PubMed Central  Google Scholar 

Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay KB, Brueckner CT, Nikiforov A, Danehy FT Jr, Streich FC Jr, Boston C, Simpson A, Jackson JW, Lin S, Danek N, Faucette RR, Raman P, Capili AD, Buckler A, Carven GJ, Schürpf T (2020) Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med 12:eaay8456. https://doi.org/10.1126/scitranslmed.aay8456

Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D (2021) Immunotherapy in advanced biliary tract cancers. Cancers (Basel) 13:1569. https://doi.org/10.3390/cancers13071569

CAS  Article  Google Scholar 

Li C, Wang B, Lu D, Jin JY, Gao Y, Matsunaga K, Igawa Y, Nijem I, Lu M, Strasak A, Chernyukhin N, Girish S (2016) Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. Cancer Chemother Pharmacol 78(3):547–558. https://doi.org/10.1007/s00280-016-3099-2

CAS  Article  PubMed  Google Scholar 

Venkatakrishnan K, Burgess C, Gupta N, Suri A, Takubo T, Zhou X, DeMuria D, Lehnert M, Takeyama K, Singhvi S, Milton A (2016) Toward optimum benefit-risk and reduced access lag for cancer drugs in Asia: a global development framework guided by clinical pharmacology principles. Clin Transl Sci 9(1):9–22. https://doi.org/10.1111/cts.12386

CAS  Article  PubMed  PubMed Central  Google Scholar 

Venkatakrishnan K, Cook J (2018) Driving access to medicines with a totality of evidence mindset: an opportunity for clinical pharmacology. Clin Pharmacol Ther 103(3):373–375. https://doi.org/10.1002/cpt.926

Article  PubMed  Google Scholar 

Walsh R, Goh BC (2019) Population diversity in oncology drug responses and implications to drug development. Chin Clin Oncol 8(3):24. https://doi.org/10.21037/cco.2019.05.01

Article  PubMed  Google Scholar 

Wilkins JJ, Vugmeyster Y, Dussault I, Girard P, Khandelwal A (2019) Population pharmacokinetic analysis of bintrafusp alfa in different cancer types. Adv Ther 36(9):2414–2433. https://doi.org/10.1007/s12325-019-01018-0

CAS  Article  PubMed  Google Scholar 

Khandelwal A, Grisic AM, French J, Venkatakrishnan K (2022) Pharmacometrics golems: exposure-response models in oncology. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.2564

Article 

留言 (0)

沒有登入
gif